Earnings Call Summary | Novartis AG(NVS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Novartis AG(NVS.US) Q1 2024 Earnings Conference
The following is a summary of the Novartis AG (NVS) Q1 2024 Earnings Call Transcript:
以下是諾華股份公司（NVS）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Novartis reported Q1 2024 sales were up 11% in constant currencies.
Core operating income increased by 22% pushing towards their goal of 40% by 2027.
Core earnings per share grew by 23% to $1.80 driven by the share buyback program.
Free cash flow is expected to grow approximately in line with core operating income for 2024.
The company returned $7.6 billion to shareholders via dividends in Q1.
Novartis upgraded its guidance expecting net sales to grow in the range of high-single digit to low-double digit, and core operating income to grow in the range of low-double digit to mid-teens.
諾華報告稱，按固定貨幣計算，2024年第一季度的銷售額增長了11％。
核心營業收入增長了22％，朝着到2027年達到40％的目標邁進。
受股票回購計劃的推動，每股核心收益增長了23％，達到1.80美元。
預計自由現金流將與2024年的核心營業收入大致持平。
該公司在第一季度通過分紅向股東返還了76億美元。
諾華上調了預期，預計淨銷售額將在高個位數至低兩位數的範圍內增長，核心營業收入將在低兩位數至十幾位數的範圍內增長。
Business Progress:
業務進展：
Novartis announced a strong start to several new initiatives including the launch of Fabhalta in Europe.
Key brands Entresto, Kesimpta, Cosentyx, and Kisqali demonstrated broad-based growth.
Novartis announced two acquisitions in Q1: MorphoSys and Arvinas.
The company made significant progress in their pipeline with multiple submissions and readouts.
The company is planning on increasing investment in their four main therapeutic areas.
Novartis expects to file for and launch Kisqali, in the second half of the year.
Uptake in the first line setting for Scemblix is anticipated to be modest early on.
The ongoing Phase 3 study on ianalumab is expected to yield promising results in treating ITP.
諾華宣佈了包括在歐洲推出Fabhalta在內的多項新舉措的良好開端。
主要品牌Entresto、Kesimpta、Cosentyx和Kisqali表現出廣泛的增長。
諾華在第一季度宣佈了兩項收購：MorphoSys和Arvinas。
該公司在準備工作中取得了重大進展，提交了多份文件和宣讀報告。
該公司正計劃增加對四個主要治療領域的投資。
諾華預計將在下半年申請並推出Kisqali。
預計在早期階段，Scemblix在第一行設置中的吸收率將不高。
正在進行的關於ianalumab的3期研究預計將在治療ITP方面產生令人鼓舞的結果。
More details: Novartis AG IR
更多詳情： 諾華股份公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。